Fuzionaire

Fuzionaire is a molecular science company applying chemistry discoveries to medicine, energy, and materials. Its core technology is an ionic alkali metal (IAM) platform based on newly described abilities of Earth-abundant alkali salts to act as catalysts and reagents, which the company says drives new chemical transformations and amplifies existing chemical processes. The company positions the platform's bond-making and bond-breaking chemistry as applicable across otherwise unrelated industries, with stated target applications in new medicines and diagnostic tracers, clean fuels and energy efficiency, and materials science.

The company's core intellectual property derives from a series of discoveries made at Caltech in the laboratory of Nobel laureate Robert H. Grubbs, together with scientists at UCLA and other institutions. Fuzionaire operates alongside affiliated entities, including Fuzionaire Theranostics (Fuzionaire Tx), a chemistry-led radiopharmaceutical company that applies Fuzionaire's silicon chemistry to develop the HetSiFA platform and other SiFA radiopharmaceutical platforms. A separate affiliate, Fuzionaire Diagnostics, has been described as developing customized molecular imaging agents for non-invasive detection and localization of cancer and other diseases.

Fuzionaire Theranostics develops chemically matched diagnostic and therapeutic pairs from disease-targeting peptides and other ligands, linking fluorine-18 PET imaging with radioligand therapy to support patient selection, biodistribution assessment, and prospective dosimetry. HetSiFAs enable PET diagnostics with fluorine-18 or gallium-68, while HetSiFA-based therapeutics are developed for lutetium-177 radioligand therapy, with selective evaluation of terbium-161 and lead-212. Its lead program, FTX-426, targets GRPR-expressing solid tumors including prostate and breast cancer and is designed as a matched fluorine-18/lutetium-177 theranostic pair; the company is also exploring endocyclic SiFA architectures and undisclosed additional oncology programs.

Founding story

Fuzionaire was formed to address challenges in medicine, energy, and materials at a molecular level, building on a series of chemistry discoveries at Caltech in the laboratory of Nobel laureate Robert H. Grubbs together with scientists at UCLA and other institutions. It was co-founded by Nick Slavin, a former Skadden Arps and Norton Rose Fulbright corporate attorney and Yale and Harvard Law School graduate who serves as CEO, and by serial entrepreneur Nova Spivack. The affiliated Fuzionaire Theranostics was founded to translate silicon chemistry from the Grubbs lab into radiopharmaceutical development; its HetSiFA technology was invented by Christopher Waldmann while a postdoc at UCLA's Crump Institute for Molecular Imaging in collaboration with the Grubbs laboratory.

Business model

Fuzionaire operates as an applied research and molecular science lab that develops platform chemistry and commercializes it through affiliated operating companies, including Fuzionaire Theranostics in radiopharmaceuticals and Fuzionaire Diagnostics in molecular imaging agents. Fuzionaire Theranostics states that its oncology development paths are designed to support strategic collaboration and invites inquiries regarding platform, pipeline, and collaboration opportunities.

Traction

Fuzionaire Theranostics has a lead development program, FTX-426, a matched fluorine-18/lutetium-177 theranostic targeting GRPR-expressing solid tumors, plus undisclosed additional oncology programs enabled by the HetSiFA platform. The company reports working with academic, clinical, and industrial collaborators, and its team includes inventors with peer-reviewed publications in journals including Theranostics, PNAS, and Nature.

Latest developments

Fuzionaire Theranostics is advancing its HetSiFA platform toward matched PET and radioligand therapy programs, with FTX-426 as the lead candidate for GRPR-expressing solid tumors, selective evaluation of terbium-161 and lead-212 as therapeutic radionuclides, and exploration of endocyclic SiFA architectures.